Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Künstliche Intelligenz lässt die Nachfrage explodieren - so profitieren Anleger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Tradegate
28.05.24
19:22 Uhr
5,504 Euro
-0,196
-3,44 %
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,5785,71807:44
5,5785,71807:44

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.BioCryst spikes after a series of insider purchases12
15.05.Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare movers39
15.05.OPEN, BCRX and AWIN among pre-market gainers3
14.05.BioCryst Pharmaceuticals, Inc.: BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology5
13.05.Biocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema Attacks-
13.05.BioCryst Pharmaceuticals, Inc.: ORLADEYO (berotralstat) Approved in Mexico59RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS)...
► Artikel lesen
07.05.BioCryst Pharmaceuticals, Inc.: BioCryst to Present at Upcoming Investor Conferences2
07.05.Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday5
06.05.Earnings call: BioCryst exceeds Q1 expectations, raises ORLADEYO guidance2
06.05.BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance4
06.05.BioCryst surges 18% on quarterly earnings, adjusted guidance outlook5
06.05.BioCryst Pharmaceuticals beats top-line and bottom-line estimates; updates FY24 outlook5
06.05.BioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update288-Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million- -Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) - -Pipeline programs...
► Artikel lesen
06.05.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
03.05.BioCryst Pharmaceuticals Q1 2024 Earnings Preview4
03.05.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)68RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
22.04.BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2024 Financial Results on May 67
18.04.FYBR, BCRX and SABR are among after hour movers4
17.04.BioCryst: Brazilian Health Regulatory Agency Approves ORLADEYO1
17.04.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency402RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval...
► Artikel lesen
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3